NCT05879978View on ClinicalTrials.gov

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

December 26, 2025

Study Completion Date

December 26, 2025

Conditions
Small Cell Lung Carcinoma (SCLC)Neuroendocrine Neoplasms
Interventions
DRUG

Obrixtamig

Obrixtamig

DRUG

Ezabenlimab

Ezabenlimab

Trial Locations (8)

1200

Cliniques Universitaires Saint-Luc, Brussels

9000

UNIV UZ Gent, Ghent

14000

CTR François Baclesse, Caen

31059

INS Claudius Regaud IUCT-Oncopole, Toulouse

60590

Universitätsklinikum Frankfurt, Frankfurt

69677

HOP Louis Pradel, Bron

01307

Technische Universität Dresden, Dresden

104-0045

National Cancer Center Hospital, Tokyo, Chuo-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05879978 - A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Biotech Hunter | Biotech Hunter